SavedAdd your journal

Journals / Retina-Vitreus / 2013 / Cilt: 21 - Sayı: 2

Development of posterior vitreous detachment during age- related macular degeneration treatment and ıt’s effect on treatment

Yaşa bağlı maküla dejeneresansı tedavisinde arka vitreus dekolmanı gelişimi ve tedavi üzerindeki etkisi

Güner ÜNEY ÖZKAN
Nurten ÜNLÜ
Mehmet Akif ACAR
Dicle HAZIROLAN
Züleyha AKKAYA YALNIZ
UĞUR EMRAH ALTIPARMAK
Firdevs ÖRNEK
Pages
109–112
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Development of PVD can effect positively the anatomical and visual prognosis during AMD treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To evaluate the rate of posterior vitreous detachment (PVD) development in patients who recieved intravitreal injections for age-related macular degeneration (AMD) and to compare the visual and anatomical results with the patients not developed PVD.
📊
Key Findings & Data:The rate of PVD development was detected.
💡
Conclusion & Impact:Conclusion: Development of PVD can effect positively the anatomical and visual prognosis during AMD treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To evaluate the rate of posterior vitreous detachment (PVD) development in patients who recieved intravitreal injections for age-related macular degeneration (AMD) and to compare the visual and anatomical results with the patients not developed PVD. Materials and Methods: Medical records of patients who recieved intravitreal anti vascular endothelial growth factor (anti- VEGF) treatment for AMD were evaluated retrospectively. According to the fundoscopic examination, .ultrasonography (USG) and optical coherence tomography (OCT) records patients without PVD were included to the study. The rate of PVD development was detected. The visual acuity (VA) and central foveal thickness (CFT) initially, at 3rd,6th,9th,12th months and at final visit were evalu- ated. Results: The mean age of 35 patients was 69.6±8.9 years. Five cases (%14.3) developed PVD during the follow up. The median (minimum-maximum) VA of the patients without PVD (PVD-) at 3rd,6th,9th,12th month and at last visit was 57.5 (15-85), 61.5 (16- 88), 55 (3-88), 42 (1-87), 42.5 (7-85), 34 (1-83) letters respectively. Visual acuity of the patients who developed PVD (PVD+) was 57 (44-69), 72 (66-77), 68 (57-77), 70 (50-75), 65 (55-78) and 52 (20-70) letters respectively. The CFT (minimum-maximum) in the PVD- group was 300 (149-589), 198 (128-484), 219.5 (100-555), 246 (145-513), 217 (146-606), 241 (128-517) μm, in the PVD+ group it was 252 (187-814), 156 (115-520), 173 (135-287), 219 (144-225), 225 (191-332), 231 (94-296) μm respectively. Posterior vitreous detachment developed after a median (minimum-maximum) of 6 (3-9) injections. Conclusion: Development of PVD can effect positively the anatomical and visual prognosis during AMD treatment.

Özet

Amaç: Yaşa bağlı maküla dejeneresansı (YBMD) nedeni ile intravitreal enjeksiyon uygulanan olgularda arka vitreus dekolmanı (AVD) gelişme oranını saptamak ve AVD gelişmeyen olgularla görsel ve anatomik sonuçları karşılaştırmak. Gereç ve Yöntem: YBMD nedeniyle intravitreal anti vasküler endotel büyüme faktörü (anti-VEBF) tedavisi uygulanan hastala- rın dosyaları geriye dönük olarak incelendi. Fundus muayenesi, oküler ultrasonografi (USG) ve optik koherens tomografi (OKT) kayıtlarına göre PVD bulunmayan olgular çalışmaya dahil edildi. Takiplerde PVD gelişme oranı saptandı. Olguların başlangıç, enjeksiyon sonrası 3, 6, 9, 12. ay ve son takiplerindeki görme keskinliği (GK) ve santral fovea kalınlıkları (SFK) değerlendirildi. Bulgular: Otuz beş olgunun yaş ortalaması 69.6±8.9 idi. Beş (%14.3) olguda takiplerde AVD gelişti. AVD gelişmeyen olgularda (AVD-) sırası ile başlangıç, 3, 6, 9, 12. aydaki ve son muayenedeki median (minimum-maksimum) GK 57.5 (15-85), 61.5 (16-88), 55 (3-88), 42 (1-87), 42.5 (7-85), 34 (1-83) harf idi. AVD gelişen olgularda (AVD+) ise sırası ile GK, 57 (44-69), 72 (66-77), 68 (57-77), 70 (50-75), 65 (55-78) ve 52 (20-70) harfdi. AVD- grupta başlangıç, 3, 6, 9, 12. ay ve son muayenedeki median (minimum-maksimum) SFK 300 (149-589) , 198 (128-484), 219.5 (100-555), 246 (145-513), 217 (146-606), 241 (128-517) μm olarak saptanırken AVD+ grup- ta ise sırası ile 252 (187-814), 156 (115-520), 173 (135-287), 219 (144-225), 225 (191-332), 231 (94-296) μm idi. Olgularda median 6 (min:3, maks:9) enjeksiyon yapıldıktan sonra AVD geliştiği gözlendi. Sonuç: Arka vitreus dekolmanı gelişimi, anatomik ve görsel olarak prognozu olumlu yönde etkileyebilen bir faktördür.

🔖

Cite This Article

ÖZKAN, G. Ü., ÜNLÜ, N., ACAR, M. A., HAZIROLAN, D., YALNIZ, Z. A., ALTIPARMAK, U. E., ÖRNEK, F. (2013). Development of posterior vitreous detachment during age- related macular degeneration treatment and ıt’s effect on treatment. Retina-Vitreus, Cilt: 21 - Sayı: 2, 109–112. https://ajindex.com/articles/305107

References (15)

  1. Congdon N, O’Colmain B, Klaver CC et al. Eye Diseases Prev- alence Research Group. Causes and prevalence of visual im- pairment among adults in the United States. Arch Ophthal- mol 2004;122:477-85
  2. Klein R, Klein BE, Lee KE et al. Changes in visual acuity in a population over a 15-year period: the Beaver Dam Eye Study. Am J Ophthalmol 2006;142:539-49
  3. Haddad S, Chen CA, Santangelo SL et al. The genetics of age- related macular degeneration: a review of progress to date. Surv Ophthalmol 2006;51:316-63
  4. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614
  5. Chakravarthy U, Augood C, Bentham GC et al. Cigarette smoking and age-related macular degeneration in the EUREYE Study. Ophthalmology 2007;114:1157-63
  6. Krebs I, Brannath W, Glittenberg C et al. Posterior Vitreomac- ular adhesion: a potential risk factor for exudative age-related macular degeneration? Am J Ophthalmol 2007;144:741-6
  7. Ondes F, Yilmaz G, Acar MA et al. Role of the vitreous in age- related macular degenera­ ion. Jpn J Ophthalmol 2000;44:91-3. t 8. Lee SJ, Koh HJ. Effects of vitreomacular adhesion on anti- vascular endothelial growth factor treatment for exudative age-related macular degeneration. Ophthalmology 2011; 118:101-10
  8. Foos RY. Posterior vitreous detachment. Trans Am Acad Oph- thalmol Otolaryngol 1972;76:480-97
  9. Sebag J. Anomalous posterior vitreous detachment: a unify­ ing concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004;242:690-8
  10. Weber-Krause B, Eckardt C. Incidence of posterior vitreous detachment in the elderly. Ophthalmologe 1997;94:619-23
  11. Schmidt-Erfurth U, Leitgeb RA, Michels S et al. Three-dimen- sional ultra-high-resolution optical coherence tomography of macular diseases. Invest Ophthalmol Vis Sci 2005;46:3393-402
  12. Mojana F, Cheng L, Bartsch DU et al. The role of abnormal vitreomacular adhesion in age-related macular degeneration: spectral optical coherence tomography and surgical results. Am J Ophthalmol 2008;146:218-27
  13. Anderson DH, Mullins RF, Hageman GS et al. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 2002;134:411-31
  14. Donoso LA, Kim D, Frost A et al. The role of inflammation in the pathogenesis of age-related macular degeneration. Surv Ophthalmol 2006;51:137-52
  15. Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;122:598-614. 17.